Pharmacists call on state boards to act against illegal retatrutide

A commentary published September 4, 2026 in Pharmacy Times argues that state boards of pharmacy, not the FDA, hold the main power to stop clinicians and pharmacies from selling illegal retatrutide, an experimental obesity drug that has not been approved for human use ^[1].

Retatrutide is made by Eli Lilly and is still being tested in clinical trials. It is not FDA-approved, and federal law does not allow it to be compounded or sold for people to use ^[1]. Despite that, the drug is being marketed by online sellers, compounding pharmacies, and medical spas, sometimes labeled as "compounded retatrutide" and sometimes as "research use only" ^[1]. The author, pharmacist John Hertig, writes that neither label makes the product legal, and that a pharmacy or clinic connection does not change what the products actually are ^[1].

The commentary says the FDA can go after companies that illegally market unapproved drugs, but it cannot discipline the individual pharmacists, doctors, or nurse practitioners who prescribe or dispense them. That job falls to state licensing boards, which oversee pharmacies operating in their states, including nonresident pharmacies that ship products across state lines ^[1].

Some states have already acted. Ohio's pharmacy board has warned licensees that compounding, selling, ordering, or administering retatrutide could lead to discipline, including immediate license suspension, and the state has collected more than $1 million in penalties from sellers of unapproved drugs, including retatrutide ^[1]. Indiana's pharmacy board denied a nonresident pharmacy's license renewal in a case involving retatrutide, according to board minutes from April 13, 2026 ^[1]. The FDA has also identified at least one supplier, Darmerica LLC, that distributed retatrutide to pharmacies for use in compounding, based on a warning letter FDA issued in December 2025 ^[1].

The author argues these state actions cover only a small share of the illegal retatrutide moving through pharmacy channels nationwide, and calls for more coordination between state boards, the FDA, and the National Association of Boards of Pharmacy to track sellers operating across multiple states ^[1]. A separate report cited in the piece found unlicensed weight-loss drugs, including retatrutide, being promoted on social media as prizes in giveaways as early as February 2026 ^[1].

Why it matters for patients

Retatrutide has not gone through the FDA review process that checks a drug's safety, effectiveness, and manufacturing quality. Products sold under names like "compounded retatrutide" or "research use only" have not been verified as safe or accurately dosed, according to the commentary ^[1]. Patients who obtain these products from online sellers, spas, or pharmacies operating outside their license may have no assurance about what is actually in the vial or how much of it there is.

The piece also makes clear that enforcement so far is uneven. Ohio and Indiana have taken disciplinary steps, but the author says most illegal retatrutide sales are not yet being caught, because a pharmacy licensed in multiple states can keep operating in states that have not investigated it ^[1]. That means the level of oversight a patient benefits from may depend heavily on which state their pharmacy or clinic is licensed in.

What happens next

The FDA maintains a public list of its concerns about unapproved GLP-1 drugs sold for weight loss, updated as recently as September 1, 2026 ^[1]. The commentary calls for state boards to be given more resources to investigate complaints, review pharmacy licensing records across state lines, and coordinate with the FDA and each other. No specific new state or federal enforcement actions beyond those in Ohio and Indiana are detailed in the source, and it is not yet known whether other states will adopt similar measures.